Cancer Research The Future of Cancer Research: Science and Patient Impact  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 16, 262-266, March 1, 1956]
© 1956 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bennett, L. L.
Right arrow Articles by Rhoads, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bennett, L. L., Jr.
Right arrow Articles by Rhoads, C. P.

Searches for Exploitable Biochemical Differences Between Normal and Cancer Cells

II. Nucleic Acid Purine Metabolism in Human Tumors*

L. L. Bennett, Jr., Howard E. Skipper, Helene W. Toolan and C. P. Rhoads

( Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama; Sloan-Kettering Institute for Cancer Research, New York)

The incorporation of C14-labeled compounds (formate, glycine, adenine, guanine, hypoxanthine, 2,6-diaminopurine, and xanthine) into nucleic acid purines has been measured in heterologous implants of human tumors and in livers and intestines of the hosts. The tumors were a sarcoma (HS-1) and an epidermoid carcinoma (HEP-3) grown in hamsters and rats treated with cortisone.

Relative to normal tissues, both tumors employed reasonably well the de novo pathway to nucleic acid purines, failed to incorporate guanine significantly, and utilized hypoxanthine very poorly. The extent of utilization of adenine by tumors was about the same as that by liver but less than that by intestine. Diaminopurine was found to be a good precursor of nucleic acid guanine in both tumors relative to normal tissues. Xanthine was not utilized significantly by tumor or by normal tissues.

The results are in essential agreement with those obtained previously with a spectrum of mouse and rat neoplasms.

* This work was made possible by grants from the American Cancer Society, the Alfred P. Sloan Foundation, Inc., the C. F. Kettering Foundation, and the Biology and Medicine Division, U.S. Atomic Energy Commission. Presented in part before the Division of Biological Chemistry, 127th National Meeting of the American Chemical Society, Cincinnati, Ohio, March 29 to April 7, 1955.

Received 11/ 9/55.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1956 by the American Association for Cancer Research.